Amedisys (NASDAQ:AMED) had its target price hoisted by Oppenheimer from $140.00 to $150.00 in a note issued to investors on Thursday, The Fly reports. Oppenheimer’s target price suggests a potential upside of 11.06% from the company’s previous close.
Other research analysts have also issued reports about the company. ValuEngine upgraded Amedisys from a “hold” rating to a “buy” rating in a research report on Saturday, June 22nd. BidaskClub upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 26th. Jefferies Financial Group set a $150.00 price target on Amedisys and gave the stock a “buy” rating in a research report on Monday, July 8th. Finally, Raymond James raised their price target on Amedisys from $140.00 to $144.00 and gave the stock an “outperform” rating in a research report on Monday, July 15th. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $133.05.
AMED stock traded down $2.83 during midday trading on Thursday, hitting $135.06. 656,886 shares of the company’s stock were exchanged, compared to its average volume of 426,962. Amedisys has a 1-year low of $97.38 and a 1-year high of $141.98. The company’s 50-day simple moving average is $124.30. The stock has a market capitalization of $4.33 billion, a PE ratio of 37.21, a PEG ratio of 1.70 and a beta of 1.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.91.
In other Amedisys news, Director Jake L. Netterville sold 1,863 shares of Amedisys stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $118.17, for a total transaction of $220,150.71. Following the completion of the sale, the director now directly owns 73,700 shares of the company’s stock, valued at approximately $8,709,129. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Michael Paul North sold 1,183 shares of Amedisys stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $130.00, for a total value of $153,790.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,278 shares of company stock valued at $6,673,207. 2.90% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in AMED. Alpha Quant Advisors LLC lifted its holdings in Amedisys by 137.0% during the 1st quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock worth $29,000 after buying an additional 137 shares during the last quarter. CWM LLC lifted its holdings in Amedisys by 482.2% during the 2nd quarter. CWM LLC now owns 262 shares of the health services provider’s stock worth $32,000 after buying an additional 217 shares during the last quarter. Tompkins Financial Corp purchased a new stake in Amedisys during the 2nd quarter worth about $37,000. NEXT Financial Group Inc purchased a new stake in Amedisys during the 2nd quarter worth about $82,000. Finally, Meeder Asset Management Inc. increased its position in shares of Amedisys by 102.3% during the first quarter. Meeder Asset Management Inc. now owns 965 shares of the health services provider’s stock worth $120,000 after purchasing an additional 488 shares in the last quarter. 88.10% of the stock is owned by institutional investors.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Featured Article: Overbought
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.